Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.

JCO precision oncology - 1 Aug 2024

Graham Laura S, Henderson Nicholas C, Kellezi Olesia, Hwang Clara, Barata Pedro C, Bilen Mehmet A, Kilari Deepak, Pierro Michael, Thapa Bicky, Tripathi Abhishek, Mo George, Labriola Matthew, Park Joseph J, Rothstein Shoshana, Garje Rohan, Koshkin Vadim S, Patel Vaibhav G, Dorff Tanya, Armstrong Andrew J, McKay Rana R, Alva Ajjai, Schweizer Michael T

Abstract excerpt

PURPOSE: Outcomes data for DNA-damaging therapeutics for men with prostate cancer (PC) and non-BRCA1/2 homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in men with PC treated with poly(ADP-ribose)polymerase inhibitors (PARPi) and/or platinum chemotherapy. METHODS: Retrospective data from the PROMISE consortium were used. Clinical outcomes differences were...

Topics

Join the communities discussing this publication.

Aged
Aged, 80 and over
DNA Damage
BARD1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Poly(ADP-ribose) Polymerase Inhibitors

Prostatic Neoplasms

Recombinational DNA Repair

Source

Open in PubMed Open full text

Identifiers

PMID: 39178368
DOI: 10.1200/PO.24.00014
PMCID: PMC11346579

Genes

BRCA1
PC
ATM
BARD1
BRIP1
CDK12
CHEK1
CHEK2
FANCA
FANCL
GEN1
PALB2
RAD51B
RAD54L2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.PMID 39178368Read ↗

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair AlterationsSemantic proximity Read ↗

Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.Semantic proximity Read ↗

Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate CarcinomasSemantic proximity Read ↗

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read ↗

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read ↗

DNA Repair in Prostate Cancer: Biology and Clinical ImplicationsSemantic proximity Read ↗

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.Semantic proximity Read ↗

Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancerSemantic proximity Read ↗

Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patientsSemantic proximity Read ↗

Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene AberrationsSemantic proximity Read ↗

DNA-Damage-Repair Gene Alterations in Genitourinary MalignanciesSemantic proximity Read ↗

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.